GlyProVac has via its proprietary platform technology, BEMAP, discovered that 1) O-linked protein glycosylation is a surprisingly abundant post translational modification in bacterial, 2) glycoproteins are linked to increased immunogenicity. 
GlyProVac aim to be the first to explore and exploit this novel class of antigens as candidates for vaccine development. The GlyProVac lead YghJ/SslE/AcfD is a conserved protein with a known biological function and has vaccine potential not only in ETEC but also in UPEC. Using BEMAP, GlyProVac has identified 59 glycosylated residues in YghJ. We are in the PoC phase and currently work to establish that glycosylated YghJ elicit a more protective immune response compared to the non-glycosylated version.

GlyProVac

Anders Boysen

This department oversees the strategic direction and overall management of the organization.

Executive Leadership

This department focuses on scientific research and strategic oversight within the organization.

GlyProVac

Org chart

Teams

Executive Leadership

Research and Governance

Offices

GlyProVac

Org chart

Teams

Executive Leadership

Research and Governance

Offices

Related companies